MR13A9 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uremic Pruritus
Conditions
Uremic Pruritus
Trial Timeline
Feb 1, 2019 → Oct 22, 2019
NCT ID
NCT03802617About MR13A9 + Placebo
MR13A9 + Placebo is a phase 2 stage product being developed by Kissei Pharmaceutical for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT03802617. Target conditions include Uremic Pruritus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04711603 | Phase 3 | Completed |
| NCT03802617 | Phase 2 | Completed |
Competing Products
15 competing products in Uremic Pruritus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| CCX168 | Amgen | Phase 2 | 51 |
| Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 49 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 49 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine HCL ER | Trevi Therapeutics | Phase 1 | 28 |
| nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |